Search

everythinglearnresearchcommunity

for

Search:↓

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Alopecia areata involves unique activation of certain immune cells.

Higher PD-1 levels mean fewer CD8+ T cells in alopecia areata hair follicles.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

Finasteride increases CD8+ T cells in BPH tissues.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Alopecia areata in these mice is inherited, more common in young females, and can be treated with triamcinolone acetonide.

Alopecia areata is caused by the immune system attacking hair follicles.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Alopecia areata may be treated by restoring hair follicle immune privilege and adjusting immune responses.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Apremilast may help treat hair loss in alopecia areata.

JAK inhibitors might help treat alopecia areata.